Inhibition of Klebsiella β-lactamases (SHV-1 and KPC-2) by avibactam: A structural study

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Krishnan, Nikhil P ^a   Nguyen, Nhu Q ^a   Papp Wallace, Krisztina M ^b   Bonomo, Robert A ^a,b   Van Den Akker, Focco ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM; BETA LACTAMASE; BETA LACTAMASE CTX M; BETA LACTAMASE CTX M 15; BETA LACTAMASE KPC 2; BETA LACTAMASE SHV 1; CARBAPENEMASE; PENICILLINASE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; AZABICYCLO DERIVATIVE; BETA-LACTAMASE KPC-2; BETA-LACTAMASE PIT-2; LIGAND; PROTEIN BINDING; WATER;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MUTATION; BINDING AFFINITY; CONTROLLED STUDY; COVALENT BOND; CRYSTAL STRUCTURE; DEACYLATION; DRUG ACTIVITY; DRUG CONFORMATION; DRUG DEGRADATION; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME ANALYSIS; ENZYME INHIBITION; HYDROGEN BOND; KLEBSIELLA PNEUMONIAE; NONHUMAN; STEREOCHEMISTRY; STRUCTURE ANALYSIS; BACTERIAL CHROMOSOME; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; KINETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MOLECULAR MODEL; STEREOISOMERISM; X RAY CRYSTALLOGRAPHY;

AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CATALYTIC DOMAIN; CHROMOSOMES, BACTERIAL; CRYSTALLOGRAPHY, X-RAY; HYDROGEN BONDING; KINETICS; KLEBSIELLA PNEUMONIAE; LIGANDS; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; PROTEIN BINDING; STEREOISOMERISM; WATER;

EID: 84945218862     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136813     Document Type: Article

References (36)

1. Bush K. The ABCD's of beta-lactamase nomenclature. Journal of infection and chemotherapy: official journal of the Japan Society of Chemotherapy. 2013; 19(4):549-59. doi: 10.1007/s10156-013-0640-7 PMID: 23828655.
2. Drawz SM, Bonomo RA. Three decades of β-lactamase inhibitors. Clin Microbiol Rev. 2010; 23(1):160-201.
3. Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Kern G, et al. Avibactam is a covalent, reversible, nonbeta-lactam beta-lactamase inhibitor. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(29):11663-8. doi: 10.1073/pnas.1205073109 PMID: 22753474; PubMed Central PMCID: PMC3406822.
4. Padayatti PS, Helfand MS, Totir MA, Carey MP, Carey PR, Bonomo RA, et al. High resolution crystal structures of the trans-enamine intermediates formed by sulbactam and clavulanic acid and E166A SHV-1 β-lactamase. J Biol Chem. 2005; 280(41):34900-7.
5. Padayatti PS, Helfand MS, Totir MA, Carey MP, Hujer HM, Carey PR, et al. Tazobactam forms a stoichiometric trans-enamine intermediate in the E166A variant of SHV-1 β-lactamase: 1.63 Å crystal structure. Biochemistry. 2004; 43:843-8. PMID: 14744126
6. Kuzin AP, Nukaga M, Nukaga Y, Hujer A, Bonomo RA, Knox JR. Inhibition of the SHV-1 β-lactamase by sulfones: crystallographic observation of two reaction intermediates with tazobactam. Biochemistry. 2001; 40(6):1861-6. PMID: 11327849
7. Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Durand-Reville TF, et al. Kinetics of avibactam inhibition against Class A, C, and D beta-lactamases. The Journal of biological chemistry. 2013; 288(39):27960-71. doi: 10.1074/jbc.M113.485979 PMID: 23913691; PubMed Central PMCID: PMC3784710.
8. Castanheira M, Williams G, Jones RN, Sader HS. Activity of ceftaroline-avibactam tested against contemporary Enterobacteriaceae isolates carrying beta-lactamases prevalent in the United States. Microbial drug resistance. 2014; 20(5):436-40. doi: 10.1089/mdr.2013.0181 PMID: 24593056.
9. Endimiani A, Hujer KM, Hujer AM, Pulse ME, Weiss WJ, Bonomo RA. Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2011; 55(1):82-5.
10. Endimiani A, Choudhary Y, Bonomo RA. In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob Agents Chemother. 2009; 53(8):3599-601.
11. Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2011; 55(1):390-4.
12. Bush K. Proliferation and significance of clinically relevant β-lactamases. Ann NY Acad Sci. 2013; 1277:84-90.
13. Livermore DM. Current epidemiology and growing resistance of gram-negative pathogens. Korean J Intern Med. 2012; 27(2):128-42.
14. Deshpande LM, Rhomberg PR, Sader HS, Jones RN. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: Report from the MYSTIC Program (1999-2005). Diagn Microbiol Infect Dis. 2006; 56:367-72.
15. Bratu S, Mooty M, Nichani S, Landman D, Gullans C, Pettinato B, et al. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob Agents Chemother. 2005; 49(7):3018-20.
16. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013; 13 (9):785-96.
17. Ke W, Bethel CR, Thomson JM, Bonomo RA, van den Akker F. Crystal structure of KPC-2: insights into carbapenemase activity in class A β-lactamases. Biochemistry. 2007; 46(19):5732-40. PMID: 17441734
18. Ke W, Bethel CR, Papp-Wallace KM, Pagadala SR, Nottingham M, Fernandez D, et al. Crystal structures of KPC-2 β-lactamase in complex with 3-nitrophenyl boronic acid and the penam sulfone PSR-3-226. Antimicrob Agents Chemother. 2012; 56(5):2713-8.
19. Papp-Wallace KM, Winkler ML, Taracila MA, Bonomo RA. Variants of the KPC-2 beta-lactamase which are resistant to inhibition by avibactam. Antimicrobial agents and chemotherapy. 2015;Epub 9-Feb-2015. doi: 10.1128/AAC.04406-14 PMID: 25666153.
20. Winkler ML, Papp-Wallace KM, Taracila MA, Bonomo RA. Avibactam and inhibitor resistant SHV betalactamases. Antimicrobial agents and chemotherapy. 2015;Epub 17-Feb-2015. Epub 17-Feb-2015. doi: 10.1128/AAC.04405-14 PMID: 25691639.
21. Xu H, Hazra S, Blanchard JS. NXL104 irreversibly inhibits the beta-lactamase from Mycobacterium tuberculosis. Biochemistry. 2012; 51(22):4551-7. doi: 10.1021/bi300508r PMID: 22587688; PubMed Central PMCID: PMC3448018.
22. Lahiri SD, Mangani S, Jahic H, Benvenuti M, Durand-Reville TF, De Luca F, et al. Molecular Basis of Selective Inhibition and Slow Reversibility of Avibactam against Class D Carbapenemases: A Structure-Guided Study of OXA-24 and OXA-48. ACS chemical biology. 2015; 10(2):591-600. doi: 10.1021/cb500703p PMID: 25406838.
23. Lahiri SD, Mangani S, Durand-Reville T, Benvenuti M, De Luca F, Sanyal G, et al. Structural Insight into Potent Broad-spectrum Inhibition with Reversible Recyclization Mechanism: Avibactam in Complex with CTX-M-15 and Pseudomonas aeruginosa AmpC beta-lactamases. Antimicrob Agents Chemother. 2013; 57:2496-505.
24. King DT, King AM, Lal SM, Wright GD, Strynadka NC. Molecular mechanism of avibactam mediated beta-lactamase inhibition. ACS Infect Dis. 2015; 1:10. Epub 22-Jan-2015
25. Padayatti PS, Sheri A, Totir MA, Helfand MS, Carey MP, Anderson VE, et al. Rational design of a β-lactamase inhibitor achieved via stabilization of the trans-enamine intermediate: 1.28Å crystal structure of wt SHV-1 complex with a penam sulfone. J Am Chem Soc. 2006; 128(40):13235-42.
26. Petrella S, Ziental-Gelus N, Mayer C, Renard M, Jarlier V, Sougakoff W. Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. Antimicrob Agents Chemother. 2008; 52(10):3725-36.
27. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997; 276:307-26.
28. Vagin A, Teplyakov A. Molecular replacement with MOLREP. Acta CrystallogrDBiolCrystallogr. 2010; 66(Pt 1):22-5.
29. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta CrystallogrDBiolCrystallogr. 1997; 53(Pt 3):240-55.
30. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta CrystallogrDBiolCrystallogr. 2004; 60(Pt 12 Pt 1):2126-32.
31. Schuttelkopf AW, van Aalten DM. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta CrystallogrDBiolCrystallogr. 2004; 60(Pt 8):1355-63.
32. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK-a program to check the stereochemical quality of protein structures. JApplCryst. 2001; 26:283-91.
33. Sgrignani J, Grazioso G, De Amici M, Colombo G. Inactivation of TEM-1 by avibactam (NXL-104): insights from quantum mechanics/molecular mechanics metadynamics simulations. Biochemistry. 2014; 53(31):5174-85. doi: 10.1021/bi500589x PMID: 25050826.
34. Rodkey EA, Drawz SM, Sampson JM, Bethel CR, Bonomo RA, van den Akker F. Crystal structure of a pre-acylation complex of the b-lactamase inhibitor sulbactam bound to a sulfenamide bond-containing thiol-beta-lactamase. J Am Chem Soc. 2012; 134:16798-804.
35. Winkler ML, Rodkey EA, Taracila M, Drawz SM, Bethel C, Papp-Wallace K, et al. Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase. J Med Chem. 2013; 56:1084-97.
36. Rydberg P, Jorgensen MS, Jacobsen TA, Jacobsen AM, Madsen KG, Olsen L. Nitrogen inversion barriers affect the N-oxidation of tertiary alkylamines by cytochromes P450. Angewandte Chemie. 2013; 52 (3):993-7. doi: 10.1002/anie.201206207 PMID: 23192954.